Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Instagram Outage Disrupts Thousands of U.S. Users 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
CAMBRIDGE, Mass., April 18, 2017 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the first quarter ended March 31, 2017 before the U.S. financial markets open on Tuesday, May 2, 2017.
Management will host a conference call on that date at 10:00 a.m. EDT to discuss these results and provide an update on the company. To access the call, please dial (877) 224-9084 (domestic) or (720) 545-0022 (international) prior to the scheduled conference call time and provide the access code 9265541. A live webcast of the call will be available on the "Investors" section of the company's website, www.momentapharma.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
